Key result
Hormonal contraception guidelines for women with non-cardiovascular comorbidities are updated to address lower dose pills and the increased incidence of conditions like metabolic syndrome.
Why the study?
Previous ACOG guidelines on hormonal contraception in women with pre-existing conditions were out of date, and CDC point-form guidelines lacked context for clinical rationale.
This review provides updated evidence on the use of hormonal contraception in women with non-cardiovascular comorbidities to supplement existing CDC guidelines.
Answers are grounded in this paper and cite their sources.
Adopt CDC US MEC for contraceptive decisions in women with comorbidities; extends outdated ACOG bulletin with current point-form guidance.
INTRODUCTION: Previously, the American College of Obstetrics and Gynecology (ACOG) had published an excellent practice bulletin addressing the use of hormone contraception in women with pre-existing medical conditions. This practice bulletin became out of date. The Centers for Disease Control and prevention (CDC) of the USA subsequently developed a point form guideline for the use of oral contraceptives in women with coexisting medical conditions. EVIDENCE ACQUISITION: Although this acts as a guide, it leaves the clinician without an understanding of why they are doing what they are doing. This article is one of two related to women with coexisting medical conditions. EVIDENCE SYNTHESIS: In this article we will provide an update of the scientific knowledge since the publication of the ACOG guideline (2006). It is to be used as a supplement for those who desire more information than that found in the CDC guidelines. CONCLUSIONS: Although some recommendations have remained unchanged over the years, the development of lower dose contraceptive pills as well as the increased incidence of comorbid conditions, such as metabolic syndrome, in younger women seeking contraception has brought along new research and new evidence to guide clinicians in the prescription of these medications.
No takes yet. Share an insight, caveat, or question.
Feinberg et al. (2020) conducted a review in Non-cardiovascular coexisting medical conditions. Hormonal contraception was evaluated. Hormonal contraception guidelines for women with non-cardiovascular comorbidities are updated to address lower dose pills and the increased incidence of conditions like metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: